## Amgen's Tavneos Faces Safety Scrutiny in Japan After 20 Reported Deaths
Amgen's microscopic polyangiitis treatment Tavneos has encountered serious safety concerns in Japan following reports that 20 patients died after taking the drug. The Japanese distribution partner has begun discouraging its use, marking a significant setback for the medication's rollout in the world's third-largest pharmaceutical market.

Tavneos, approved in Japan in 2022 for patients with severe cases of the rare autoimmune disease ANCA-associated vasculitis, represents a key commercial asset for Amgen following its 2019 acquisition of Otezla. The drug works as an adjunctive treatment targeting the inflammatory condition that damages small blood vessels. However, post-marketing surveillance data collected through Japan's dedicated adverse drug reaction reporting system has now flagged a pattern that has prompted swift action from the local partner.

Crucially, investigators have not established whether Tavneos directly caused the fatalities. Patients suffering from microscopic polyangiitis typically face severe health complications, and disentangling deaths attributable to disease progression from those potentially linked to treatment remains a complex medical assessment. The reporting mechanism captures temporal associations without confirming causation, leaving open questions about the precise relationship between the drug and the mortality data.

The development places Amgen under pressure to provide clarity on Tavneos's safety profile. The company must address the Japanese findings while navigating regulatory scrutiny from the Pharmaceuticals and Medical Devices Agency. Market observers note that similar safety signals have emerged in other jurisdictions where the drug is approved. The outcome of ongoing investigations could influence prescribing patterns, reimbursement negotiations, and the drug's long-term commercial trajectory beyond Japan.
---
- **Source**: Japan Times
- **Sector**: The Lab
- **Tags**: pharmaceutical, drug safety, Japan, adverse events, clinical risk
- **Credibility**: unverified
- **Published**: 2026-05-16 03:48:22
- **ID**: 83706
- **URL**: https://whisperx.ai/en/intel/83706